Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 12/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12777173 | 0.88 | FGFR1 (0.65) | FGFR1HPGDGABRA1GABRG2GABRB3 | |
| SCHEMBL2648918 | 0.88 | GABRA1 (0.52) | FGFR1HPGDGABRA1GABRG2GABRB3 | |
| SCHEMBL2650743 | 0.83 | GABRA1 (0.70) | FGFR1HPGDGABRA1GABRG2GABRB3 | |
| SCHEMBL2648966 | 0.81 | FGFR1 (0.66) | FGFR1HPGDGABRA1GABRG2GABRB3 | |
| SCHEMBL2643507 | 0.80 | GABRA1 (0.69) | FGFR1HPGDGABRA1GABRG2GABRB3 | |
| SCHEMBL2650210 | 0.80 | FGFR1 (0.65) | FGFR1HPGDGABRA1GABRG2GABRB3 | |
| SCHEMBL2655078 | 0.78 | HPGD (0.38) | FGFR1HPGDGABRA1GABRG2GABRB3 | |
| SCHEMBL2650727 | 0.78 | FGFR1 (0.68) | FGFR1HPGDGABRA1GABRG2GABRB3 | |
| SCHEMBL23680877 | 0.77 | FGFR1 (0.76) | FGFR1HPGDALDH1A1 | |
| SCHEMBL13002361 | 0.77 | FGFR1 (0.76) | FGFR1HPGDNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1023286-A1 | BENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS AND THEIR USE | NEUROSEARCH A/S (DK) | 2000-08-02 | — | — | EP | claimed |
| WO-1999019323-A1 | BENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS AND THEIR USE | NEUROSEARCH A/S (DK) | 1999-04-22 | — | — | WO | claimed |
| US-8288418-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2012-10-16 | — | — | US | disclosed |
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2011-05-19 | — | — | US | disclosed |
| EP-2319837-A1 | Benzimidazole derivatives and their use for modulating the GABAa receptor complex | NeuroSearch AS (DK) | 2011-05-11 | — | — | EP | disclosed |
| EP-2001855-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2010-11-03 | — | — | EP | disclosed |
| WO-2007110374-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | WO | disclosed |
| EP-1023286-A1 | BENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS AND THEIR USE | NEUROSEARCH A/S (DK) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999019323-A1 | BENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS AND THEIR USE | NEUROSEARCH A/S (DK) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | GABRB2, GABRB1, GABRB3 | FGFR1 3907/4885HPGD 1966/4885GABRA1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.